INSERM, IRD, SESSTIM, Sciences Economiques & Sociales de la Santé & Traitement de l'Information Médicale, Aix Marseille Université, 27 Bd Jean Moulin, 13005 Marseille, France.
ORS PACA, Observatoire Régional de la Santé Provence-Alpes-Côte d'Azur, 27 Bd Jean Moulin, 13005 Marseille, France.
Nutrients. 2018 May 31;10(6):705. doi: 10.3390/nu10060705.
Coffee intake has been shown to modulate both the effect of ethanol on serum GGT activities in some alcohol consumers and the risk of alcoholic cirrhosis in some patients with chronic diseases. This study aimed to analyze the impact of coffee intake and alcohol consumption on advanced liver fibrosis (ALF) in HIV-HCV co-infected patients.
ANRS CO13-HEPAVIH is a French, nationwide, multicenter cohort of HIV-HCV-co-infected patients. Sociodemographic, behavioral, and clinical data including alcohol and coffee consumption were prospectively collected using annual self-administered questionnaires during five years of follow-up. Mixed logistic regression models were performed, relating coffee intake and alcohol consumption to ALF.
1019 patients were included. At the last available visit, 5.8% reported high-risk alcohol consumption, 27.4% reported high coffee intake and 14.5% had ALF. Compared with patients with low coffee intake and high-risk alcohol consumption, patients with low coffee intake and low-risk alcohol consumption had a lower risk of ALF (aOR (95% CI) 0.24 (0.12–0.50)). In addition, patients with high coffee intake had a lower risk of ALF than the reference group (0.14 (0.03–0.64) in high-risk alcohol drinkers and 0.11 (0.05–0.25) in low-risk alcohol drinkers).
High coffee intake was associated with a low risk of liver fibrosis even in HIV-HCV co-infected patients with high-risk alcohol consumption.
咖啡摄入已被证明可以调节一些饮酒者中乙醇对血清 GGT 活性的影响,以及一些慢性病患者发生酒精性肝硬化的风险。本研究旨在分析咖啡摄入和饮酒对 HIV-HCV 合并感染患者进展性肝纤维化(ALF)的影响。
ANRS CO13-HEPAVIH 是一项法国全国性多中心的 HIV-HCV 合并感染患者队列研究。采用年度自我管理问卷,前瞻性收集社会人口统计学、行为学和临床数据,包括酒精和咖啡摄入情况,随访 5 年。采用混合逻辑回归模型,分析咖啡摄入和饮酒与 ALF 的关系。
共纳入 1019 例患者。在最后一次可获得的随访中,5.8%的患者报告存在高风险饮酒,27.4%的患者报告高咖啡摄入,14.5%的患者存在 ALF。与低咖啡摄入和高风险饮酒的患者相比,低咖啡摄入和低风险饮酒的患者 ALF 风险较低(调整后的比值比(95%CI)为 0.24(0.12-0.50))。此外,与参考组相比,高咖啡摄入的患者 ALF 风险较低(高风险饮酒者为 0.14(0.03-0.64),低风险饮酒者为 0.11(0.05-0.25))。
即使在 HIV-HCV 合并感染且有高风险饮酒的患者中,高咖啡摄入也与较低的肝纤维化风险相关。